Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Br-a657
1. 247257-48-3
2. Kanarb
3. Fimasartan [inn]
4. 2-(1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-n,n-dimethylethanethioamide
5. Chembl1951143
6. Fimasartan (inn)
7. P58222188p
8. 2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-n,n-dimethylethanethioamide
9. 2-(2-butyl-4-methyl-6-oxo-1-{[2'-(1h-tetrazol-5-yl)-4-biphenylyl]methyl}-1,6-dihydro-5-pyrimidinyl)-n,n-dimethylethanethioamide
10. Br-a657
11. Br-a-657.k
12. Unii-p58222188p
13. 5-pyrimidineethanethioamide, 2-butyl-1,6-dihydro-n,n,4-trimethyl-6-oxo-1-((2'-(2h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
14. 5-pyrimidineethanethioamide, 2-butyl-1,6-dihydro-n,n,4-trimethyl-6-oxo-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
15. Fimasartan [who-dd]
16. Schembl2229436
17. Schembl20126833
18. Dtxsid80179460
19. Chebi:136044
20. Bcp11616
21. Ex-a3997
22. Hy-b0780
23. Zinc3842872
24. Bdbm50364573
25. Mfcd13194795
26. S4975
27. Zb1816
28. Akos016011331
29. Akos037643761
30. Ccg-269705
31. Cs-3509
32. Db09279
33. Ncgc00390600-01
34. Ac-30631
35. As-35179
36. D10556
37. 257f483
38. A919293
39. L019170
40. Q8563179
41. 2-((2-butyl-4-methyl-6-oxo-1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,6-dihydropyrimidin-5-yl))-n,n-dimethylthioacetamide
42. 2-(1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-n,n-dimethylethanethioamide
43. 2-(1-((2-(2h-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-n,n-dimethylethanethioamide
44. 2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]met Hyl]pyrimidin-5-yl]-n,n-dimethylethanethioamide
45. 2-butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3h)-one
| Molecular Weight | 501.6 g/mol |
|---|---|
| Molecular Formula | C27H31N7OS |
| XLogP3 | 3.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 9 |
| Exact Mass | 501.23107981 g/mol |
| Monoisotopic Mass | 501.23107981 g/mol |
| Topological Polar Surface Area | 123 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 849 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used for the treatment of hypertension and heart failure.
Fimasartan is a selective angiotensin receptor 1 (AR1) inhibitor. It acts to lower blood pressure by inhibiting vasoconstriction
C - Cardiovascular system
C09 - Agents acting on the renin-angiotensin system
C09C - Angiotensin ii receptor blockers (arbs), plain
C09CA - Angiotensin ii receptor blockers (arbs), plain
C09CA10 - Fimasartan
Absorption
Tmax is 0.5-1.3 h.
Route of Elimination
Most is eliminated unchangd in bile with less than 3% in the urine.
The half life of elimination is 7-10 h.
Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at 1-adrenergic receptors. It also stimulates secretion of aldosterone which acts to increase sodium and water reabsorption in the renal tubules. Fimasartan bind to and antagonizes AR1 preventing vasoconstriction and reducing aldosterone secretion to increase natriuresis leading to a reduction in blood volume. Together these effects produce an anti-hypertensive effect.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
70
PharmaCompass offers a list of Fimasartan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Fimasartan manufacturer or Fimasartan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fimasartan manufacturer or Fimasartan supplier.
PharmaCompass also assists you with knowing the Fimasartan API Price utilized in the formulation of products. Fimasartan API Price is not always fixed or binding as the Fimasartan Price is obtained through a variety of data sources. The Fimasartan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fimasartan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fimasartan, including repackagers and relabelers. The FDA regulates Fimasartan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fimasartan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fimasartan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fimasartan supplier is an individual or a company that provides Fimasartan active pharmaceutical ingredient (API) or Fimasartan finished formulations upon request. The Fimasartan suppliers may include Fimasartan API manufacturers, exporters, distributors and traders.
click here to find a list of Fimasartan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fimasartan Drug Master File in Korea (Fimasartan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fimasartan. The MFDS reviews the Fimasartan KDMF as part of the drug registration process and uses the information provided in the Fimasartan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fimasartan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fimasartan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fimasartan suppliers with KDMF on PharmaCompass.
A Fimasartan written confirmation (Fimasartan WC) is an official document issued by a regulatory agency to a Fimasartan manufacturer, verifying that the manufacturing facility of a Fimasartan active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Fimasartan APIs or Fimasartan finished pharmaceutical products to another nation, regulatory agencies frequently require a Fimasartan WC (written confirmation) as part of the regulatory process.
click here to find a list of Fimasartan suppliers with Written Confirmation (WC) on PharmaCompass.
Fimasartan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fimasartan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fimasartan GMP manufacturer or Fimasartan GMP API supplier for your needs.
A Fimasartan CoA (Certificate of Analysis) is a formal document that attests to Fimasartan's compliance with Fimasartan specifications and serves as a tool for batch-level quality control.
Fimasartan CoA mostly includes findings from lab analyses of a specific batch. For each Fimasartan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fimasartan may be tested according to a variety of international standards, such as European Pharmacopoeia (Fimasartan EP), Fimasartan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fimasartan USP).
